Lipoxin belong to the family of bioactive products formed from Arachidonic acid. These lipoxins are involved in various anti-inflammatory and immunomodulatory functions. Lipoxin signalling leads to inhibition of superoxide generation, transmigration, chemotaxis and activation of NF- k B. two lipoxins namely, lipoxin A4 (LXA4) and lipoxin B4 (LXB4) are identified.

LXA (4) are produced by rat tissues, both in vitro and in vivo. LXA (4) shows a potent pathophysiological role in rats. In a study, intravenous subjection of a stable analog of LXA(4) showed a significant decrease in neutrophil infiltration. 

The increased chances of survival by decreasing systemic inflammation was investigated in another study, by Walker et al. Sepsis is the result of systemic inflammation and release of inflammatory mediators. This condition further leads to various organ failure and immunoparalysis. Immunoparalysis leads to susceptibility of the host to various opportunistic infections. Effect of lipoxin LXA (4), was investigated for its inflammatory resolution properties. 

The effect of lipoxin LXA (4) was checked in cecal ligation and puncture (CLP) sepsis model. The rats were subjected to saline or LXA (4) after 5 hour surgery. The survival rates of CLP rats subjected to Lipoxin A4 showed increased 8 day survival. Various inflammatory responses and mediators like plasma IL-6, IL-10 and monocyte chemotactic protein 1 levels were reduced in CLP rats which were subjected to lipoxin A4 when compared with CLP rats subjected to saline. 

Lipoxin LXA 4 leads to increased survival in sepsis by reduction in systemic inflammation.